2-(2,6-Dichlor-4-ethylaminophenylimino)-imidazolidin | 73218-76-5

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 2-(2,6-Dichlor-4-ethylaminophenylimino)-imidazolidin
• 英文别名: 2,6-dichloro-N¹-(4,5-dihydro-1H-imidazol-2-yl)-N⁴-ethyl-benzene-1,4-diamine；2,6-dichloro-1-N-(4,5-dihydro-1H-imidazol-2-yl)-4-N-ethylbenzene-1,4-diamine
• CAS: 73218-76-5
• 化学式: C₁₁H₁₄Cl₂N₄
• 分子量: 273.165
• InChiKey: VMODJBICTQHZIP-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.3
• 重原子数：
  17
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.36
• 拓扑面积：
  48.4
• 氢给体数：
  3
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  2-(2,6-Dichlor-4-ethylaminophenylimino)-imidazolidin 、 环氧乙烷 生成 Dichlor-2,6-ethylamino-4-N-(β-hydroxyethyl)anilino-2-imidazolin-1
  参考文献：
  名称：

  ROUOT B.; LECLERC G., BULL. SOC. CHIM. FRANCE, 1979, PART 2, NO 9-10, 520-528

  摘要：

  DOI：
• 作为产物：
  描述：

  2-(4-Acetamido-2,6-dichlorphenylimino)-imidazolidin 、 硼烷 、 二甲基硫 以53%的产率得到
  参考文献：
  名称：

  ROUOT B.; LECLERC G., BULL. SOC. CHIM. FRANCE, 1979, PART 2, NO 9-10, 520-528

  摘要：

  DOI：

文献信息

• Clonidine and/or clonidine derivatives for use in the prevention and/or treatment of adverse side effects of chemotherapy
  申请人：ONXEO

  公开号：US10675271B2

  公开（公告）日：2020-06-09

  The present invention pertains to specific clonidine and/or clonidine derivatives for use in the prevention and/or treatment of adverse side effects of alkylating agent chemotherapy, other than those resulting from mucosal inflammation. It also pertains to the use of this clonidine and/or clonidine derivative for the manufacture of a pharmaceutical composition intended to prevent and/or alleviate the adverse side effects of alkylating agent chemotherapy, other than those resulting from mucosal inflammation. This invention is further directed to a kit comprising: (a) a clonidine and/or clonidine derivative, and (b) at least one alkylating chemotherapeutic agent, as a combined preparation for simultaneous, separate or sequential use in the treatment of cancer.

  本发明涉及用于预防和/或治疗烷化剂化疗不良副作用（粘膜炎症引起的副作用除外）的特定氯尼定和/或氯尼定衍生物。本发明还涉及使用这种氯尼地定和/或氯尼地定衍生物制造药物组合物，以预防和/或减轻烷化剂化疗的不良副作用（粘膜炎症引起的副作用除外）。本发明还涉及一种试剂盒，包括：(a)一种氯尼地定和/或氯尼地定衍生物，和(b)至少一种烷化剂化疗药，作为一种联合制剂，可同时、单独或依次用于治疗癌症。
• Clonidine and/or clonidine derivatives for use in the prevention of skin injury resulting from radiotherapy
  申请人：MONOPAR THERAPEUTICS INC.

  公开号：US11090290B2

  公开（公告）日：2021-08-17

  The present invention pertains to a pharmaceutical composition comprising a pharmaceutically acceptable carrier and Clonidine and/or Clonidine derivatives as a sole active ingredient for use in the prevention of skin injury resulting from radiotherapy by transmucocal administration.

  本发明涉及一种药物组合物，该组合物由药学上可接受的载体和作为唯一活性成分的氯硝柳胺和/或氯硝柳胺衍生物组成，用于通过经黏膜给药预防放疗导致的皮肤损伤。
• CLONIDINE AND/OR CLONIDINE DERIVATIVES FOR USE IN THE PREVENTION AND/OR TREATMENT OF ADVERSE SIDE EFFECTS OF CHEMOTHERAPY
  申请人：Monopar Therapeutics Inc.

  公开号：EP3283072A1

  公开（公告）日：2018-02-21
• CLONIDINE AND/OR CLONIDINE DERIVATIVES FOR USE IN THE PREVENTION OF SKIN INJURY RESULTING FROM RADIOTHERAPY
  申请人：Monopar Therapeutics Inc.

  公开号：EP3294292A1

  公开（公告）日：2018-03-21
• [EN] CLONIDINE AND/OR CLONIDINE DERIVATIVES FOR USE IN THE PREVENTION AND/OR TREATMENT OF ADVERSE SIDE EFFECTS OF CHEMOTHERAPY<br/>[FR] CLONIDINE ET/OU DÉRIVÉS DE CLONIDINE DESTINÉ(E)S À LA PRÉVENTION ET/OU AU TRAITEMENT D'EFFETS SECONDAIRES INDÉSIRABLES D'UNE CHIMIOTHÉRAPIE
  申请人：ONXEO

  公开号：WO2016165775A1

  公开（公告）日：2016-10-20

  The present invention pertains to specific clonidine and/or clonidine derivatives for use in the prevention and/or treatment of adverse side effects of alkylating agent chemotherapy, other than those resulting from mucosal inflammation. It also pertains to the use of this clonidine and/or clonidine derivative for the manufacture of a pharmaceutical composition intended to prevent and/or alleviate the adverse side effects of alkylating agent chemotherapy, other than those resulting from mucosal inflammation. This invention is further directed to a kit comprising: (a) a clonidine and/or clonidine derivative, and (b) at least one alkylating chemotherapeutic agent, as a combined preparation for simultaneous, separate or sequential use in the treatment of cancer.